Stock comparison
Genmab A/S
Sotera Health
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
SHC
Sotera Health
Market cap
$4.47B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | SHC | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 58D | GMAB |
| Benjamin Graham | 64C | 84D | SHC |
| Philip Fisher | 48D | 53C | SHC |
| Peter Lynch | 25F | 36D | SHC |
| Joel Greenblatt | 76B | 30F | GMAB |
| Charlie Munger | 68C | 60D | GMAB |
| Terry Smith | 71C | 58D | GMAB |
Side-by-side metrics
| Metric | GMAB | SHC |
|---|---|---|
| Market cap | $16.5B | $4.47B |
| P/E (TTM) | 6.2x | 36.9x |
| EV/EBIT | 12.0x | 16.1x |
| ROIC (TTM) | 43.78% | 7.96% |
| Gross margin | 93.88% | 55.01% |
| Net margin | 18.23% | 9.91% |
| Revenue CAGR 5y | -18.45% | 5.72% |
| EPS CAGR 5y | -23.48% | -9.92% |
| Debt / Equity | 0.1x | 3.6x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Debt / Equity0.1xvs 3.6x+98%
- P/E (TTM)6.2xvs 36.9x+83%
- ROIC (TTM)43.78%vs 7.96%+82%
- Market cap$16.5Bvs $4.47B+73%
SHC leads on
- Revenue CAGR 5y5.72%vs -18.45%+131%
- EPS CAGR 5y-9.92%vs -23.48%+58%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.